Thyroid CancerNCT02347683
Optimal Measurement of Thyroglobulin Measurement Following Thyroidectomy
An observational study of Thyroid Cancer, run by University of Nebraska at 1 site in United States.
Trial summary
The optimal timing to measure thyroglobulin(Tg) after thyroidectomy is unknown in patients with thyroid cancer. The ATA and NCCN guidelines are not specific on optimal timing of Tg levels in post-op state and suggest anywhere between 2-12 weeks. Hypothesis - Post -op Tg nadirs at 6-8 weeks . Read more about this study
- Who is it for?
- Ages 19 years and olderHealthy volunteers can take part
- Conditions the study is for
- Thyroid Cancer
- How many people
- 50 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Jan 2015to 1 Feb 2016
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: All adults age 19 and above already planning to undergo near total /total thyroidectomy for reasons unrelated to the study.
Who may be able to join
- All patients already planning to undergo total /near total thyroidectomy for reasons unrelated to this study.
- Age 19 or older
Who cannot join
- Children < 19 years
- Pregnancy
Trial locations and contacts
1 site in 1 country.
United States1 site
University of Nebraska Medical Center
Omaha, Nebraska, 68198
About this study
The optimal timing to measure thyroglobulin(Tg) after thyroidectomy is unknown in patients with thyroid cancer. The ATA and NCCN guidelines are not specific on optimal timing of Tg levels in post-op state and suggest anywhere between 2-12 weeks.
Hypothesis - Post -op Tg nadirs at 6-8 weeks .
Read more
Primary Objective -Determine optimal timing of post thyroidectomy Tg nadir, so to determine the most accurate time to check post operatively.
Secondary Outcome - Determine factors that will affect Tg levels post operatively.
All adults age 19 and above already planning to undergo near total /total thyroidectomy for reasons unrelated to the study.
Measure Tg , Tg Ab and TSH pre-op, post op ---> 7-14 days, 4 wk, 6 wk, and 3 month in patients with pathology confirmed benign disease.
Measure Tg , Tg Ab , TSH pre-op, post op ---> 7-14 days, 4 wk, 6 wk, 3 month, 6 month, and 12 month in patients with thyroid cancer.
Read the detailed description
Thyroid cancer, the most common endocrine tumor, constitutes 3.8% of all cancers. 62,980 new cases were estimated in the U.S. in 20141, an increasing trend from the 37,200 new cases in 20092. 90% of all thyroid cancers are differentiated thyroid carcinomas (DTC), which include both papillary and follicular thyroid carcinoma3.
Management of DTC involves a total thyroidectomy, with possible central and lateral neck dissection if there are clinical lymph node involvement, except for low-risk lesions that are unifocal, intrathyroidal, node-negative and measuring less than 1 cm in size. Radioactive iodine ablation of any remnant thyroid tissue may follow a total thyroidectomy depending on the risk stratification of the patient3. As for any cancer, management of thyroid cancer involves long-term surveillance for early detection of disease recurrence3.
According to the ATA guidelines, postoperative surveillance includes regular (every 6 to 12 months) clinical evaluation for tumor recurrence, evaluation with neck ultrasound and serum Thyroglobulin (Tg) levels while on levothyroxine replacement3. Serum Tg has become a very useful and well-acknowledged marker in patients with thyroid cancer post thyroidectomy for disease persistence, metastasis or recurrence.
Thyroglobulin is a 660 kDa dimeric glycoprotein that is exclusively produced and stored by thyroid follicular cells in benign conditions, but also by well-differentiated thyroid cancer cells4. A total thyroidectomy for higher risk patients is thus not only is important to provide definitive treatment and decrease risk of recurrence, but also allows for long term follow-up with Tg levels.
One study has reported Tg is eliminated through the liver and its half-life following total thyroidectomy has been reported to be about 65.2 hours. The Tg level was noted to decrease to less than 5-10 ng/ml 25 days after thyroidectomy, or after 7 to 10 half-lives in 11 patient samples5. Detection of Tg following the total thyroidectomy during long-term surveillance would therefore suggest persistent thyroid tissue.
Despite the determined half-life of Tg, in a retrospective study with 36 patients with low-risk papillary thyroid carcinoma, the unstimulated Tg level fell to < 0.5 ng/ml after 6 months postoperatively in only 61%, and after 2 years postoperatively in 100% of the patients6. No prospective studies have yet determined the nadir of the Tg level post thyroidectomy. In our personal clinical experience, unstimulated serum Tg levels may be found undetectable 6 to 12 weeks following a total thyroidectomy.
The sensitivity, specificity, positive predictive value and negative predictive value of unstimulated (normal or low TSH ) serum Tg in assessing completeness of thyroidectomy (< 0.5 ng/ml) have been reported to be 70%, 100%, 100% and 92% respectively6. Obtaining a basal unstimulated serum Tg level post thyroidectomy not only determines the completeness of the total thyroidectomy7, but also provides a basal level for future comparison during long-term surveillance. The high negative predictive value allows for the identification of patients less likely to have disease recurrence and provide less aggressive and more cost effective management strategies3.
The optimal time to obtain an unstimulated serum Tg level has not yet been determined. Obtaining the Tg level too early following the total thyroidectomy may result in a misleadingly significant Tg level and erroneously suggest residual disease, thereby leading to unnecessary further investigation and more aggressive management strategies. NCCN guidelines suggest to check anywhere between 2-12 weeks in patients with thyroid cancer 8
Radioactive iodine ablation of remnant thyroid tissue may potentially be avoided with a postsurgical stimulated Tg level of < 1ng/ml in low risk, well-differentiated thyroid cancer9. This practice is not yet approved by the American Thyroid Association, and is less likely to be feasible with no concensus on the timing of the Tg measurement.
The objective of this study is therefore to find the nadir of the unstimulated serum Tg level following total thyroidectomy, and therefore the optimal time for Tg measurement in postoperative surveillance.
- Conditions
- Thyroid Cancer
- Medical subject headings
- Thyroid Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Benign pathology | We will measure serum Tg , Tg Ab levels , and TSH at 7-14 days, 4, 6, and 12 weeks | |
| Malignant pathology | We will measure serum Tg , Tg Ab levels , and TSH at 7-14 days ; 4, 6, and 12 weeks and 6 and 12 months |
What is being measured
The primary outcome is the main question the study is designed to answer.
Optimal timing of post thyroidectomy thyroglobulin (Tg) nadir
Determine optimal timing of post thyroidectomy thyroglobulin (Tg) nadir, so to determine the most accurate time to check post operatively.
Measured: within a year
Secondary outcomes (1)
Factors affecting thyroglobulin (Tg) levels post operatively
Determine factors that will affect thyroglobulin (Tg) levels post operatively
Measured: within a year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jan 2015 (estimated)
- Study start1 Jan 2015
- Primary completion1 Feb 2016
- Study completion1 Feb 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Thyroid CancerStudies of the same condition, open and under way.
- More trials run by University of NebraskaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 50 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Nebraska
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Whitney Goldner, MD, Principal investigator, University of Nebraska
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02347683
- Sponsor's protocol ID
- 0594-14-FB
- Status last verified
- Aug 2023
- First submitted
- 21 Jan 2015
- Last updated
- 5 Sep 2023
- Results posted
- No
- Data monitoring committee
- No
Publications
Patel A, Shostrom V, Treude K, Lydiatt W, Smith R, Goldner W. Serum Thyroglobulin: Preoperative Levels and Factors Affecting Postoperative Optimal Timing following Total Thyroidectomy. Int J Endocrinol. 2019 Feb 20;2019:1384651. doi: 10.1155/2019/1384651. eCollection 2019.
PubMed 30915112
Study at a glance
From the registry record, last updated by the sponsor on 5 Sep 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Optimal Measurement of Thyroglobulin Measurement Following Thyroidectomy
- ClinicalTrials.gov ID
- NCT02347683
- Acronym / sponsor ID
- 0594-14-FB
- Conditions
- Thyroid Cancer
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 50 participants (actual)
- Lead sponsor
- University of NebraskaUniversity, hospital or other
- Study start
- 1 Jan 2015 (actual)
- Primary completion
- 1 Feb 2016 (actual)
- Study completion
- 1 Feb 2016 (actual)
- First posted
- 27 Jan 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The optimal timing to measure thyroglobulin(Tg) after thyroidectomy is unknown in patients with thyroid cancer. The ATA and NCCN guidelines are not specific on optimal timing of Tg levels in post-op state and suggest anywhere between 2-12 weeks.
Hypothesis - Post -op Tg nadirs at 6-8 weeks .
Primary Objective -Determine optimal timing of post thyroidectomy Tg nadir, so to determine the most accurate time to check post operatively.
Secondary Outcome - Determine factors that will affect Tg levels post operatively.
All adults age 19 and above already planning to undergo near total /total thyroidectomy for reasons unrelated to the study.
Measure Tg , Tg Ab and TSH pre-op, post op ---> 7-14 days, 4 wk, 6 wk, and 3 month in patients with pathology confirmed benign disease.
Measure Tg , Tg Ab , TSH pre-op, post op ---> 7-14 days, 4 wk, 6 wk, 3 month, 6 month, and 12 month in patients with thyroid cancer.
Detailed description
Thyroid cancer, the most common endocrine tumor, constitutes 3.8% of all cancers. 62,980 new cases were estimated in the U.S. in 20141, an increasing trend from the 37,200 new cases in 20092. 90% of all thyroid cancers are differentiated thyroid carcinomas (DTC), which include both papillary and follicular thyroid carcinoma3.
Management of DTC involves a total thyroidectomy, with possible central and lateral neck dissection if there are clinical lymph node involvement, except for low-risk lesions that are unifocal, intrathyroidal, node-negative and measuring less than 1 cm in size. Radioactive iodine ablation of any remnant thyroid tissue may follow a total thyroidectomy depending on the risk stratification of the patient3. As for any cancer, management of thyroid cancer involves long-term surveillance for early detection of disease recurrence3.
According to the ATA guidelines, postoperative surveillance includes regular (every 6 to 12 months) clinical evaluation for tumor recurrence, evaluation with neck ultrasound and serum Thyroglobulin (Tg) levels while on levothyroxine replacement3. Serum Tg has become a very useful and well-acknowledged marker in patients with thyroid cancer post thyroidectomy for disease persistence, metastasis or recurrence.
Thyroglobulin is a 660 kDa dimeric glycoprotein that is exclusively produced and stored by thyroid follicular cells in benign conditions, but also by well-differentiated thyroid cancer cells4. A total thyroidectomy for higher risk patients is thus not only is important to provide definitive treatment and decrease risk of recurrence, but also allows for long term follow-up with Tg levels.
One study has reported Tg is eliminated through the liver and its half-life following total thyroidectomy has been reported to be about 65.2 hours. The Tg level was noted to decrease to less than 5-10 ng/ml 25 days after thyroidectomy, or after 7 to 10 half-lives in 11 patient samples5. Detection of Tg following the total thyroidectomy during long-term surveillance would therefore suggest persistent thyroid tissue.
Despite the determined half-life of Tg, in a retrospective study with 36 patients with low-risk papillary thyroid carcinoma, the unstimulated Tg level fell to < 0.5 ng/ml after 6 months postoperatively in only 61%, and after 2 years postoperatively in 100% of the patients6. No prospective studies have yet determined the nadir of the Tg level post thyroidectomy. In our personal clinical experience, unstimulated serum Tg levels may be found undetectable 6 to 12 weeks following a total thyroidectomy.
The sensitivity, specificity, positive predictive value and negative predictive value of unstimulated (normal or low TSH ) serum Tg in assessing completeness of thyroidectomy (< 0.5 ng/ml) have been reported to be 70%, 100%, 100% and 92% respectively6. Obtaining a basal unstimulated serum Tg level post thyroidectomy not only determines the completeness of the total thyroidectomy7, but also provides a basal level for future comparison during long-term surveillance. The high negative predictive value allows for the identification of patients less likely to have disease recurrence and provide less aggressive and more cost effective management strategies3.
The optimal time to obtain an unstimulated serum Tg level has not yet been determined. Obtaining the Tg level too early following the total thyroidectomy may result in a misleadingly significant Tg level and erroneously suggest residual disease, thereby leading to unnecessary further investigation and more aggressive management strategies. NCCN guidelines suggest to check anywhere between 2-12 weeks in patients with thyroid cancer 8
Radioactive iodine ablation of remnant thyroid tissue may potentially be avoided with a postsurgical stimulated Tg level of < 1ng/ml in low risk, well-differentiated thyroid cancer9. This practice is not yet approved by the American Thyroid Association, and is less likely to be feasible with no concensus on the timing of the Tg measurement.
The objective of this study is therefore to find the nadir of the unstimulated serum Tg level following total thyroidectomy, and therefore the optimal time for Tg measurement in postoperative surveillance.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Benign pathology | – | –We will measure serum Tg , Tg Ab levels , and TSH at 7-14 days, 4, 6, and 12 weeks |
| Malignant pathology | – | –We will measure serum Tg , Tg Ab levels , and TSH at 7-14 days ; 4, 6, and 12 weeks and 6 and 12 months |
Who may qualify
- Ages
- 19 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- All adults age 19 and above already planning to undergo near total /total thyroidectomy for reasons unrelated to the study.
Key inclusion criteria (2 listed)
- All patients already planning to undergo total /near total thyroidectomy for reasons unrelated to this study.
- Age 19 or older
Key exclusion criteria (2 listed)
- Children < 19 years
- Pregnancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Optimal timing of post thyroidectomy thyroglobulin (Tg) nadir
Time frame: within a year
Determine optimal timing of post thyroidectomy thyroglobulin (Tg) nadir, so to determine the most accurate time to check post operatively.
1 secondary outcome
Factors affecting thyroglobulin (Tg) levels post operatively
Time frame: within a year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Sep 2023.
- Derived from this study: PubMed 30915112Patel A, Shostrom V, Treude K, Lydiatt W, Smith R, Goldner W. Serum Thyroglobulin: Preoperative Levels and Factors Affecting Postoperative Optimal Timing following Total Thyroidectomy. Int J Endocrinol. 2019 Feb 20;2019:1384651. doi: 10.1155/2019/1384651. eCollection 2019.
Related trials for Thyroid Cancer
Recruiting
NIRAF-Guided Parathyroid Identification During Thyroidectomy
Hypocalcemia, Hypoparathyroidism
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
Not yet recruitingPhase 1/2
177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
Thyroid Cancer
RecruitingObservational study
DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study
Pleuropulmonary Blastoma, Cystic Nephroma
Recruiting
Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules
Thyroid Gland Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Whitney Goldner, MD principal investigator
University of Nebraska
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Thyroid Cancer, run by University of Nebraska at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Optimal timing of post thyroidectomy thyroglobulin (Tg) nadir (time frame: within a year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02347683, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Sep 2023.